Monoclonal antibodies represent the vanguard of targeted therapy due to their specificity and versatility. Aside from disrupting tumor cell survival and proliferation through cell surface receptor interactions, antibodies ...

Cancer cells become resistant to monoclonal antibody (mAb) therapy when they lose the cell surface antigens that mAbs target. To circumvent immune escape and maximize the efficacy of mAb therapy, new approaches to mitigate ...

Immunotherapy has revolutionized cancer treatment. Certain immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapy, provide long lasting remissions. Unfortunately, the majority of tumors are unresponsive ...

Upon cognate antigen encounter, naïve (antigen-inexperienced) B cells activate shifting from a state of quiescence to rapid clonal expansion and differentiation into germinal center (GC) B cells, antibody-secreting plasma ...

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, has a low mutational burden with few actionable somatic targets. Fibroblast growth factor receptor 4 (FGFR4) is a candidate therapeutic target in ...